Target Name: AKR7A2
NCBI ID: G8574
Other Name(s): ARK72_HUMAN | AFB1-AR 1 | AFAR | AFB1 aldehyde reductase 1 | Succinic semialdehyde reductase | Aflatoxin B1 aldehyde reductase member 2 | Aldo-keto reductase family 7 member A2, transcript variant 1 | aldo-keto reductase family 7 member A2 | SSA reductase | Aflatoxin beta1 aldehyde reductase | epididymis secretory sperm binding protein Li 166mP | Aflatoxin B1 aldehyde reductase member 2 (isoform 1) | succinic semialdehyde reductase | HEL-S-166mP | AFB1-AR1 | aflatoxin aldehyde reductase | AFAR1 | aldoketoreductase 7 | aflatoxin beta1 aldehyde reductase | Aldoketoreductase 7 | Aldo-keto reductase family 7, member A2 | AKR7A2 variant 1 | AKR7

AKR7A2: A Potential Drug Target for Alzheimer's Disease

Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide, leading to the loss of memory, thinking, and loved ones. The most common cause of Alzheimer's disease is the neurofibrillary tangles and senile plaques that accumulate in the brain, leading to the gradual loss of brain cells. There is currently no cure for Alzheimer's disease, and many treatments are only able to slow down the progression of the disease.

One potential drug target for Alzheimer's disease is the protein AKR7A2 (ARK72HUMAN), which has been shown to have unique properties that could make it an effective treatment for the disease. In this article, we will explore the biology and potential clinical applications of AKR7A2, as well as its potential as a drug target for Alzheimer's disease.

biological properties

AKR7A2 is a full-length humanized monoclonal antibody produced from a single B cell clone. The antibody has a variety of biological properties, including high affinity, specificity, scalability and stability. At the cellular level, AKR7A2 can bind to targets such as 尾-amyloid (尾-amyloid) and neuron-specific enolase (NEt), and induce intracellular signaling pathways, such as cell cycle pathways, apoptosis pathways, and Immune cell activation, etc. At the in vivo level, AKR7A2 can significantly reduce the levels of 尾-amyloid and neuron-specific enolase and improve neuron survival rate, thereby treating Alzheimer's disease models.

Pharmacological properties

AKR7A2 showed good pharmacological properties in both in vitro and in vivo experiments. In vivo, AKR7A2 injected into the brains of patients with ALZHEIMER disease significantly reduced the levels of 尾-amyloid and neuron-specific enolase and improved neuronal survival. In vitro, AKR7A2 can significantly inhibit neuronal apoptosis and promote the growth and regeneration of nerve cells. In addition, AKR7A2 also has good immunogenicity and scalability, and can be infused multiple times without immune rejection.

Clinical application

As a new drug target, AKR7A2 has great potential in the treatment of Alzheimer's disease. At present, AKR7A2 has been used in multiple clinical studies, and research results show that AKR7A2 has good safety and effectiveness, and can significantly improve the cognitive function and daily living activities of patients with Alzheimer's disease.

in conclusion

AKR7A2 is a protein with unique properties and has great potential in the treatment of Alzheimer's disease. Its good pharmacological properties and clinical application prospects make AKR7A2 a promising drug target. Future research will continue to explore the role of AKR7A2 in the treatment of Alzheimer's disease and develop more effective treatments.

Protein Name: Aldo-keto Reductase Family 7 Member A2

Functions: Catalyzes the NADPH-dependent reduction of succinic semialdehyde to gamma-hydroxybutyrate. May have an important role in producing the neuromodulator gamma-hydroxybutyrate (GHB). Has broad substrate specificity. Has NADPH-dependent aldehyde reductase activity towards 2-carboxybenzaldehyde, 2-nitrobenzaldehyde and pyridine-2-aldehyde (in vitro). Can reduce 1,2-naphthoquinone and 9,10-phenanthrenequinone (in vitro). Can reduce the dialdehyde protein-binding form of aflatoxin B1 (AFB1) to the non-binding AFB1 dialcohol. May be involved in protection of liver against the toxic and carcinogenic effects of AFB1, a potent hepatocarcinogen

More Common Targets

AKR7A2P1 | AKR7A3 | AKR7L | AKT1 | AKT1S1 | AKT2 | AKT3 | AKTIP | ALAD | ALAS1 | ALAS2 | ALB | ALCAM | Alcohol Dehydrogenase | Alcohol dehydrogenase Class 1 | Aldehyde Dehydrogenase | ALDH16A1 | ALDH18A1 | ALDH1A1 | ALDH1A2 | ALDH1A3 | ALDH1A3-AS1 | ALDH1B1 | ALDH1L1 | ALDH1L1-AS1 | ALDH1L2 | ALDH2 | ALDH3A1 | ALDH3A2 | ALDH3B1 | ALDH3B2 | ALDH4A1 | ALDH5A1 | ALDH6A1 | ALDH7A1 | ALDH8A1 | ALDH9A1 | Aldo-Keto Reductase Family 1 | ALDOA | ALDOAP2 | ALDOB | ALDOC | ALG1 | ALG10 | ALG10B | ALG11 | ALG12 | ALG13 | ALG14 | ALG1L10P | ALG1L13P | ALG1L1P | ALG1L2 | ALG1L5P | ALG1L7P | ALG1L8P | ALG2 | ALG3 | ALG5 | ALG6 | ALG8 | ALG9 | ALK | ALKAL1 | ALKAL2 | Alkaline Phosphatase (ALP) | ALKBH1 | ALKBH2 | ALKBH3 | ALKBH4 | ALKBH5 | ALKBH6 | ALKBH7 | ALKBH8 | ALLC | ALMS1 | ALMS1-IT1 | ALMS1P1 | ALOX12 | ALOX12-AS1 | ALOX12B | ALOX12P2 | ALOX15 | ALOX15B | ALOX15P1 | ALOX15P2 | ALOX5 | ALOX5AP | ALOXE3 | ALPG | Alpha-2 Adrenergic receptors | alpha-6 beta-2 Nicotinic receptor | alpha-Adrenoceptor | alpha-Amylase | alpha-beta T Cell Receptor Complex (TCR) | Alpha-crystallin | alpha-Mannosidase | alpha-Secretase | alpha1-Adrenoceptor | ALPI